Ara-290 is a synthetic peptide derived from the three-dimensional structure of erythropoietin (EPO), engineered specifically to activate the tissue-protective receptor complex without stimulating erythropoiesis. This selective activation profile has made Ara-290 peptide research one of the more compelling areas in neuroprotection and metabolic biology, with preclinical models investigating its influence on small fiber neuropathy, inflammation resolution, and cellular repair mechanisms. Unlike native EPO, Ara-290 targets the innate repair receptor (IRR) — a heteromeric complex distinct from the classic EPO receptor — positioning it as a structurally unique tool for researchers studying receptor-specific signaling pathways.
Interest in Ara-290 has grown steadily through 2025 and into 2026, particularly among researchers exploring tissue-protective mechanisms that operate independently of hematopoietic activity. Its relatively compact 11-amino acid sequence and high receptor selectivity make it a tractable model compound for dissecting EPO-derived biology at the cellular and molecular level.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. Ara-290 is not approved for human use and is intended exclusively for in vitro and preclinical in vivo research settings.
Ara-290 10MG — Research-Grade Reference Material Ara-290 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard. Nothing on…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
GHK-CU - 100MG
$55.00$41.25 with 1st order
GLP-3 (R) 30MG
$190.00$142.50 with 1st order
PT-141 - 10MG
$50.00$37.50 with 1st order
Frequently Asked Questions
What is Ara-290 peptide?
Ara-290 is an 11-amino acid synthetic peptide modeled on the helix B surface peptide of erythropoietin. It is designed to selectively activate the innate repair receptor (IRR) — a tissue-protective signaling complex — without triggering erythropoiesis or classical EPO receptor pathways. It is used exclusively in laboratory and preclinical research contexts.
How does Ara-290 differ from erythropoietin (EPO)?
Native erythropoietin activates both the classic homodimeric EPO receptor (which drives red blood cell production) and the tissue-protective heteromeric receptor complex. Ara-290 is engineered to interact specifically with the tissue-protective receptor (IRR), bypassing hematopoietic effects. This selectivity makes it a useful research tool for isolating EPO’s non-hematopoietic biological actions.
What has research shown about Ara-290 and neuroprotection?
Preclinical studies have investigated Ara-290’s potential to reduce neuroinflammation, support small fiber nerve regeneration, and attenuate neuropathic pain-associated signaling in animal models. Research in rodent models of diabetes-induced neuropathy has shown reduced markers of nerve damage and improved intraepidermal nerve fiber density in some studies.
What is the innate repair receptor (IRR)?
The innate repair receptor is a heteromeric complex composed of the EPO receptor and the beta common receptor (βc, also known as CD131). It is expressed in non-hematopoietic tissues including neurons, immune cells, and endothelial cells. Activation of the IRR by tissue-protective peptides like Ara-290 is associated with anti-apoptotic, anti-inflammatory, and regenerative signaling cascades in research models.
Has Ara-290 been studied in clinical trials?
Yes, Ara-290 has progressed into human clinical trials, primarily for sarcoidosis-associated small fiber neuropathy. Phase II trial data published in peer-reviewed journals reported improvements in corneal nerve fiber measures and neuropathic symptom scores. These findings are observational and exploratory; Ara-290 remains an investigational compound and is not approved as a therapeutic agent.
What are the primary research applications of Ara-290?
Laboratory research with Ara-290 has focused on: small fiber neuropathy models, neuroinflammation assays, metabolic regulation (including insulin sensitivity studies), wound healing and tissue repair models, and anti-apoptotic signaling pathway investigation. It is used as a tool compound to understand EPO-derived tissue-protective biology.
How is Ara-290 typically used in laboratory settings?
In preclinical research, Ara-290 has been administered via subcutaneous injection in rodent models. In vitro studies have applied it directly to cell cultures to examine receptor activation kinetics, downstream signaling (including STAT3, PI3K/Akt, and ERK pathways), and anti-apoptotic gene expression. Dosing parameters vary across study designs and are model-specific.
Is Ara-290 related to other tissue-protective peptides?
Ara-290 belongs to a class of EPO-derived helix B surface peptides (HBSPs). Related compounds include ARA-290 analogs and cyclic HBSP variants. Researchers sometimes compare its mechanism to other neuroprotective peptides; for example, Pinealon has also been investigated for neuroprotective applications through distinct peptide mechanisms.
Molecular Background: Erythropoietin’s Tissue-Protective Dimension
Erythropoietin has been recognized primarily as a hematopoietic cytokine since its characterization in the mid-20th century. However, research over the past two decades has revealed that EPO exerts a wide range of tissue-protective effects that are mechanistically separate from red blood cell production. These non-hematopoietic effects — including anti-apoptotic activity, modulation of inflammatory cascades, and support for neural and vascular repair — appear to be mediated through a distinct receptor complex: the IRR or tissue-protective receptor.
Ara-290 10MG — Research-Grade Reference Material Ara-290 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard. Nothing on…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
GHK-CU - 100MG
$55.00$41.25 with 1st order
GLP-3 (R) 30MG
$190.00$142.50 with 1st order
PT-141 - 10MG
$50.00$37.50 with 1st order
The IRR is formed by a heterodimer of the classical EPO receptor subunit and the beta common receptor (βc/CD131). This receptor complex is expressed in metabolically active, stress-sensitive tissues: peripheral neurons, retinal ganglion cells, cardiac myocytes, endothelial cells, and immune effector cells. Importantly, the hematopoietic EPO receptor homodimer has a higher binding affinity for full-length EPO than the IRR does, meaning that at physiological concentrations, EPO primarily drives erythropoiesis. Engineered peptides like Ara-290, derived from EPO’s helix B surface, are designed to preferentially engage the IRR, offering a more selective research handle on the tissue-protective signaling axis.
Ara-290’s 11-amino acid sequence corresponds to residues in EPO’s helix B domain that contact the βc subunit of the IRR. This structural specificity underpins both its receptor selectivity and its research utility as a probe of IRR-mediated biology.
Neuroprotection Research: Small Fiber Neuropathy & Neural Repair Models
Small Fiber Neuropathy Study Findings
The most extensively researched application of Ara-290 involves small fiber neuropathy (SFN) — a condition characterized by dysfunction and degeneration of small-diameter peripheral nerve fibers, including C-fibers and Aδ-fibers. These fibers are responsible for pain perception, temperature sensing, and autonomic function. In rodent models of diabetic neuropathy and sarcoidosis-associated SFN, Ara-290 administration has been associated with increased intraepidermal nerve fiber density (IENFD), reduced markers of neuroinflammation, and attenuated pain-associated behavioral responses.
A notable series of investigations explored Ara-290 in sarcoidosis patients, a population with documented high rates of SFN. Corneal confocal microscopy — a non-invasive measure of small fiber density — showed improvements in nerve fiber parameters in treated subjects compared to placebo groups, generating significant research interest in the compound’s regenerative potential for peripheral neural tissue.
Neuroinflammation Signaling Pathways
At the cellular level, Ara-290-mediated IRR activation has been shown in preclinical models to engage several downstream signaling nodes relevant to neural protection. Studies have reported activation of the PI3K/Akt pathway, which carries anti-apoptotic significance in neuronal populations. ERK1/2 signaling, associated with cellular survival and synaptic plasticity, has also been observed in response to Ara-290 in neuronal cell culture models. Additionally, JAK2/STAT3 pathway engagement — a canonical downstream effector of EPO-family cytokines — has been documented, with STAT3 target genes including those encoding anti-apoptotic proteins such as Bcl-2 and Bcl-xL.
This mechanistic profile positions Ara-290 as a useful research tool in studies examining neuropathic signaling cascades. Researchers interested in neuroprotective peptide mechanisms may find it valuable to compare these pathways to those explored in Pinealon research, which operates through distinct peptidergic mechanisms involving epiphyseal-derived tripeptides.
Anti-Inflammatory Mechanisms in Ara-290 Research
Beyond direct neuroprotection, Ara-290 research has investigated its anti-inflammatory properties in multiple preclinical models. IRR activation by Ara-290 has been reported to suppress pro-inflammatory cytokine expression — including TNF-α, IL-6, and IL-1β — in macrophage and microglia culture models. This cytokine suppression appears to occur through NF-κB pathway modulation, a central regulatory node in innate immune responses.
In models of acute tissue injury, Ara-290 has shown capacity to reduce neutrophil infiltration and limit secondary inflammatory damage — a profile that overlaps conceptually with tissue-protective peptides studied in wound healing contexts. Researchers who have examined similar anti-inflammatory tissue-protective activity may recognize parallels with the mechanisms explored in BPC-157 laboratory research, though the receptor targets and structural biology are entirely distinct. The convergence of these research fields on shared outcomes — reduced inflammation, accelerated tissue repair — reflects a broader scientific interest in peptide-mediated resolution biology.
Ara-290 10MG for research applications →
Metabolic Research Applications
Insulin Sensitivity & Glucose Regulation Studies
An emerging area of Ara-290 research concerns its potential effects on metabolic parameters, particularly insulin sensitivity and glucose homeostasis. The IRR is expressed in pancreatic islet cells and metabolically active tissues, and preclinical studies have explored whether Ara-290 administration influences beta-cell survival, insulin secretion dynamics, and peripheral glucose uptake in diabetic animal models.
Some rodent studies have reported improvements in insulin sensitivity markers and partial preservation of islet architecture following Ara-290 treatment in models of type 1 and type 2 diabetes. These findings remain preliminary and are interpreted within strict preclinical frameworks. The intersection of neuropathy research and metabolic research in the Ara-290 literature reflects the compound’s utility as a tool for studying how tissue-protective EPO receptor signaling connects neural and endocrine biology.
Researchers focusing on metabolic peptide science may find useful comparative context in the growing literature on GLP peptides; the GLP-1, GLP-2 & GLP-3 research guide provides a useful overview of receptor-specific metabolic signaling for cross-referencing with Ara-290’s IRR-mediated metabolic data.
Wound Healing & Tissue Repair
Ara-290 has also been investigated in dermal wound healing models, where IRR activation appears to promote keratinocyte migration, endothelial proliferation, and angiogenesis. These effects align with the known tissue-protective functions of EPO in vascular biology, suggesting that Ara-290 activates overlapping repair programs in peripheral tissue contexts. Researchers studying multi-peptide regenerative models may wish to compare these tissue-level outcomes with data from GLOW stack research, which combines GHK-Cu, BPC-157, and TB-500 in regenerative biology frameworks.
Source Ara-290 10MG for preclinical research →
Receptor Pharmacology: IRR Selectivity & Signaling Profile
One of the defining characteristics of Ara-290 as a research compound is its reported selectivity for the IRR over the classical homodimeric EPO receptor. This selectivity is attributed to the structural correspondence between Ara-290’s sequence and the βc-contacting surface of EPO’s helix B domain. In binding assays, Ara-290 demonstrates preferential affinity for βc-containing receptor complexes, while exhibiting minimal stimulation of erythropoiesis in rodent and in vitro models — a key differentiator from full-length EPO and early EPO analogs.
This receptor pharmacology profile makes Ara-290 valuable for researchers seeking to isolate tissue-protective EPO biology from hematopoietic confounds. The ability to activate anti-inflammatory and neuroprotective cascades without altering red blood cell parameters is a significant advantage in study designs requiring metabolic or neurological endpoints without hematological complications.
Downstream signaling studies have confirmed that Ara-290 activates a partially overlapping but distinct transcriptional response compared to full-length EPO, suggesting that the IRR represents a biologically meaningful signaling node rather than a lower-affinity version of the classical receptor. This has important implications for understanding EPO biology more broadly and for the rational design of future tissue-protective peptide tools.
Laboratory Considerations for Ara-290 Research
Stability & Storage
As a synthetic 11-amino acid peptide, Ara-290 exhibits moderate stability under appropriate storage conditions. Lyophilized preparations are typically stored at -20°C, with reconstituted solutions used within short timeframes to minimize degradation. Researchers should use sterile reconstitution buffers appropriate to the downstream assay and avoid repeated freeze-thaw cycles to preserve peptide integrity.
In Vitro Model Selection
Ara-290 research has been conducted across a range of cell culture models, including dorsal root ganglion (DRG) neurons, macrophage cell lines, human microvascular endothelial cells (HMVECs), and pancreatic beta-cell lines. Confirming IRR expression (via Western blot or flow cytometry for EpoR and βc subunits) in the chosen cell model is recommended before interpreting Ara-290 bioactivity data.
Comparator Peptides
Researchers designing Ara-290 experiments may benefit from including appropriate comparator peptides. Cyclic HBSP (a cyclized EPO helix B peptide) has been used as a comparator in some studies. For researchers interested in broader neuroprotective peptide comparisons, compounds such as those examined in SS-31 mitochondrial targeting research offer alternative mechanistic frameworks for cross-study design.
Ara-290 10MG research peptide →
Where These Fit in Your Research Library
Researchers working with Ara-290 in neuroprotective or metabolic frameworks may also find the following compounds relevant to their laboratory programs:
Pinealon 20MG — neuroprotective peptide research →
BPC-157 10MG Nasal Spray — tissue repair research →
Thymosin Alpha-1 10MG — immune and regenerative research →
Browse the complete SourcePeptides research peptide catalog for additional tool compounds across neuroprotection, metabolic biology, and tissue repair research areas.
Final Takeaway: Ara-290 as a Research Tool in 2026
Ara-290 occupies a distinctive position in the peptide research landscape. Its structural derivation from erythropoietin, combined with its engineered selectivity for the innate repair receptor, makes it a precise tool for investigating tissue-protective EPO signaling in isolation from hematopoietic effects. Preclinical research has built a substantive body of evidence across neuroprotection, neuroinflammation, metabolic regulation, and wound healing models, with clinical trial data in sarcoidosis-associated small fiber neuropathy adding a translational dimension rarely seen in research peptide literature.
For laboratory researchers, Ara-290’s well-characterized receptor pharmacology, manageable molecular size, and accumulating mechanistic dataset make it a compelling compound for studies at the intersection of neuroimmunology, peripheral nerve biology, and EPO receptor pharmacology. As IRR biology continues to attract scientific attention in 2026, Ara-290 remains one of the most tractable and well-defined tools available for probing this receptor system in preclinical models.
Sources & Further Reading
- Brines M et al. — “Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin” — Proceedings of the National Academy of Sciences (2008)
- Dahan A et al. — “ARA 290, a novel erythropoietin receptor agonist, improves small-fiber neuropathy in sarcoidosis” — Sarcoidosis, Vasculitis and Diffuse Lung Diseases (2014)
- Brines M & Cerami A — “The receptor that tames the innate immune response” — Molecular Medicine (2012)
- PubMed Search — Ara-290 neuropathy research literature
- PubMed Search — Erythropoietin innate repair receptor signaling studies
